title: Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial.
abstract: The response to pegylated interferon (pegIFN) plus ribavirin (RBV) as treatment of chronic hepatitis C virus (HCV) infection is lower in HIV-coinfected than in HCV-monoinfected patients and could be due to suboptimal RBV dosing and/or insufficient duration of therapy in prior trials. In a prospective, multicenter, open, comparative trial, HCV/HIV-coinfected patients received pegIFN plus weight-based RBV for 48 or 72 weeks (HCV genotypes 1 and 4) and 24 or 48 weeks (HCV genotypes 2 and 3). Use of didanosine was not allowed. Out of 389 patients included in the trial, 61% were infected by HCV-1/4 and 67% had serum HCV-RNA >500,000 IU/ml. Sustained virological response (SVR) was achieved by 49.6%, significantly higher in HCV-2/3 than HCV-1/4 (72.4% vs. 35%; p < 0.0001). A high drop-out rate in the longer treatment arms precluded obtaining definitive conclusions about the efficacy of prolonging therapy. Premature treatment discontinuations due to serious adverse events occurred in 8.2%. Infection with HCV-2/3, lower baseline HCV-RNA, and negative HCV-RNA at week 12 were all independent predictors of SVR in the multivariate analysis. The use of RBV 1000-1200 mg/day plus pegIFN is relatively safe and provides SVR in nearly half of coinfected patients, twice as high in HCV-2/3 than HCV-1/4.
authors.affiliation: Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain.
authors.forename: Marina
authors.initials: M
authors.lastname: Núñez
authors.forename: Celia
authors.initials: C
authors.lastname: Miralles
authors.forename: Miguel Angel
authors.initials: MA
authors.lastname: Berdún
authors.forename: Elena
authors.initials: E
authors.lastname: Losada
authors.forename: Koldo
authors.initials: K
authors.lastname: Aguirrebengoa
authors.forename: Antonio
authors.initials: A
authors.lastname: Ocampo
authors.forename: Piedad
authors.initials: P
authors.lastname: Arazo
authors.forename: Manuel
authors.initials: M
authors.lastname: Cervantes
authors.forename: Ignacio
authors.initials: I
authors.lastname: de Los Santos
authors.forename: Isabel
authors.initials: I
authors.lastname: San Joaquín
authors.forename: Santiago
authors.initials: S
authors.lastname: Echeverría
authors.forename: María José
authors.initials: MJ
authors.lastname: Galindo
authors.forename: Victor
authors.initials: V
authors.lastname: Asensi
authors.forename: Pablo
authors.initials: P
authors.lastname: Barreiro
authors.forename: Julio
authors.initials: J
authors.lastname: Sola
authors.forename: Juan José
authors.initials: JJ
authors.lastname: Hernandez-Burruezo
authors.forename: Josep Maria
authors.initials: JM
authors.lastname: Guardiola
authors.forename: Miriam
authors.initials: M
authors.lastname: Romero
authors.forename: Javier
authors.initials: J
authors.lastname: García-Samaniego
authors.forename: Vincent
authors.initials: V
authors.lastname: Soriano
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D005260:Female; D006678:HIV; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000821:virology; D016174:Hepacivirus / Q000187:drug effects; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011446:Prospective Studies; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a